Stock listing

Dusseldorf:ICY Incyte Corporation Aktie

German listing (Dusseldorf) of Incyte Corporation · home listing NASDAQ:INCY

Follow Incyte Corporation into a list and get an email when it puts out news.

Share price · DUS:ICY

€107.55 EUR +3.80 (+3.7%)

Close on Oct 30, 2026

Day range
€104.35 – €108.45 EUROct 30, 2026
Market cap
€13.79B EURAt the close on Oct 30, 2026 · price × 128.2M shares outstanding
Incyte Corporation logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:INCY · Home$120.39 USD+3.59 (+3.1%)2,840,308$120.10$122.87$119.55$116.80Close on Oct 30, 2026
LSE:0J9P$115.86 USD-0.28 (-0.2%)2,483$115.00$116.26$111.00$116.14Close on Oct 27, 2026
Frankfurt:ICY€104.15 EUR+3.60 (+3.6%)33€104.15€104.15€104.15€100.55Close on Oct 30, 2026
Dusseldorf:ICY€107.55 EUR+3.80 (+3.7%)—€104.70€108.45€104.35€103.75Close on Oct 30, 2026
Munich:ICY€101.85 EUR-1.55 (-1.5%)—€101.85€101.85€101.85€103.40Close on Oct 27, 2026
Ticker
Dusseldorf:ICY
Asset type
Stock
Exchange
Dusseldorf
Currency
EUR

What changed lately

Calls

Replays

  • Incyte (NASDAQ:INCY) Q3 2026 Earnings Call

    Thu, Oct 29, 2026 · 8:00 AM ET

    Watch Transcript

  • Incyte (NASDAQ:INCY) Q2 2026 Earnings Call

    Tue, Jul 28, 2026 · 8:00 AM ET

    Watch Transcript

  • Incyte (NASDAQ:INCY) Q1 2026 Earnings Call

    Tue, Apr 28, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates

Oct 29, 2026

Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026

Oct 26, 2026

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Oct 24, 2026

Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Oct 24, 2026

Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

Oct 18, 2026

Incyte to Report Third Quarter Financial Results

Oct 8, 2026

Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio

Sep 22, 2026

Incyte Announces Funding of MINJUVI® (tafasitamab) for patients with Relapsed or Refractory Follicular Lymphoma through Ontario's FAST Program

Sep 10, 2026

Incyte - Opzelura Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis

Jul 30, 2026

Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates

Jul 28, 2026

All Incyte Corporation news

Decks

Incyte Corporation on 6ix

News releases
55 in the last 12 months · 311 in all · newest Oct 29, 2026 · oldest 2019
Calls
27 calls with a replay · 27 with a transcript · latest Oct 29, 2026
Decks
35 decks · latest Oct 29, 2026

Where Incyte Corporation is listed

ListingExchangeCountryCurrency
NASDAQ:INCY · Home listingNASDAQUnited StatesUSD
gettex:ICYgettexGermanyEUR
Tradegate:ICYTradegateGermanyEUR
LSE:0J9PLSEUnited KingdomUSD
BMV:INCYBMVMexicoMXN
Frankfurt:ICYFrankfurtGermanyEUR
LS Exchange:896133LS ExchangeGermanyEUR
Lang & Schwarz:896133Lang & SchwarzGermanyEUR
Milan:1INCYMilanItalyEUR
BX Swiss:ICYBX SwissSwitzerlandCHF
B3:I1NC34B3BrazilBRL
BIVA:INCYBIVAMexicoMXN
EUROTLX:4INCYEUROTLXItalyEUR
Dusseldorf:ICY · This pageDusseldorfGermanyEUR
BOATS:INCYBOATSUnited StatesUSD
Hamburg:ICYHamburgGermanyEUR
Hanover:ICYHanoverGermanyEUR
Munich:ICYMunichGermanyEUR
Stuttgart:ICYStuttgartGermanyEUR
Turquoise:INCYNTurquoiseUnited KingdomUSD
Xetra:ICYXetraGermanyEUR

Log in to ask 6ix AI your own questions about Incyte Corporation.